Skip to main content

Advertisement

SpringerLink
Log in

Investigation of a novel biomarker, neuropilin-1, and its application for poor prognosis in acute myeloid leukemia patients

  • Research Article
  • Published:
Tumor Biology

Abstract

According to the previous studies, numerous biomarkers impact on the prognosis of acute myeloid leukemia (AML) and the prediction for AML had been improved tremendously in the past decades. However, accurate risk-stratification at diagnosis or prognosis remained difficult. In order to further investigate the prognosis evaluation biomarker, the transcription or expression of neuropilin-1 (NRP-1) in 87 AML patients and 32 non-malignant controls were examined. Real-time quantitative polymerase chain reaction (RT-PCR) and Western blot were used to detect the NRP-1 expression. Clinical data were collected and analyzed for the 87 AML patients. The results indicated that high NRP-1 expression discriminated the complete remission (CR) rate of AML patients (22.12 % vs. 68.04 % for AML, P < 0.01). De novo AML patients tended to express higher NRP-1 proteins than relapsed AML patients. The overall survival (OS) and relapse-free survival (RFS) rate of the high NRP-1 expression patients decreased significantly compared with the low NRP-1 expression patients (P < 0.001). NRP-1 was revealed to be an independent risk factor for OS in AML (P = 0.003). In conclusion, NRP-1 could predict the shorter OS and RFS rate, and also related with the CR response in AML. Therefore, NRP-1 may act as a more aggressive and promising predictor for the poor prognosis of AML.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Reference

  1. Jiang L, Yu G, Meng W, Wang Z, Meng F, Ma W. Overexpression of amyloid precursor protein in acute myeloid leukemia enhances extramedullary infiltration by MMP-2. Tumor Biol. 2013;34(2):629–36.

    Article  CAS  Google Scholar 

  2. Tian Y, Huang Z, Wang Z, Yin C, Zhou L, Zhang L, et al. Identification of novel molecular markers for prognosis estimation of acute myeloid leukemia: over-expression of PDCD7, FIS1, Ang2 may indicate poor prognosis in pretreatment patients with acute myeloid leukemia. PLoS ONE. 2014;9(1):e84150.

    Article  PubMed Central  PubMed  Google Scholar 

  3. National cancer institute. SEER stat fact sheets: acute myeloid leukemia available from: http://seer.cancer.Gov/statfacts/html/amyl.html. Accessed June 16, 2013.

  4. Memarian A, Nourizadeh M, Masoumi F, Tabrizi M, Emami AH, Alimoghaddam K, et al. Upregulation of CD200 is associated with Foxp2 regulatory T cell expansion and disease progression in acute myeloid leukemia. Tumor Biol. 2013;34(1):531–42.

    Article  CAS  Google Scholar 

  5. Damm F, Heuser M, Morgan M, Wagner K, Gorlich K, Grosshennig A, et al. Integrative prognostic risk score in acute myeloid leukemia with normal karyotype. Blood. 2011;117(17):4561–8.

    Article  CAS  PubMed  Google Scholar 

  6. Vales A, Kondo R, Aichberger KJ, Mayerhofer M, Kainz B, Sperr WR, et al. Myeloid leukemias expression a broad spectrum of VEGF receptors including neuropilin-1 (NRP-1) and NRP-2. Leuk Lymphoma. 2007;48(10):1997–2007.

    Article  CAS  PubMed  Google Scholar 

  7. Latil A, Bieche I, Pesche S, Valeri A, Fournier G, Cussenot O. VEGF overexpression in clinically localized prostate tumors and neuropilin-1 overexpression in metastatic forms. Int J Cancer. 2000;89(2):167–71.

    Article  CAS  PubMed  Google Scholar 

  8. Lu L, Zhang L, Xiao Z, Lu S, Yang R, Han ZC. Neuropilin-1 in acute myeloid leukemia: expression and role in proliferation and migration of leukemia cells. Leuk Lymphoma. 2008;49(2):331–8.

    Article  CAS  PubMed  Google Scholar 

  9. Staber PB, Linkesch W, Zauner D, Beham-Schmid C, Guelly C, Schauer S, et al. Common alterations in the gene expression and increased proliferation in recurrent acute myeloid leukemia. Oncogene. 2004;23(4):894–904.

    Article  CAS  PubMed  Google Scholar 

  10. Kreuter M. Downregulation of neuropilin-1 in patients with acute myeloid leukemia treated with thalidomide. Eur J Haematol. 2007;79(5):392–7.

    Article  CAS  PubMed  Google Scholar 

  11. Sallam TH, EI Telbany MA, Mahmoud HM, Iskander MA. Significance of neuropilin-1 expression in acute myeloid leukemia. Turk J Haematol. 2013;30(3):300–6.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  12. Zacchigna S, Pattarini L, Zentilin L, Moimas S, Carrer A, Sinigaglia M, et al. Bone marrow cells recruited through the neuropilin-1 receptor promote arterial formation at the sites of adult neoangiogenesis in mice. J Clin Invest. 2008;118(6):2062–75.

    PubMed Central  CAS  PubMed  Google Scholar 

  13. Xu K, Wang X, Shi Q, Chen C, Tian C, Li XL, et al. Human prion protein mutants with deleted and inserted octarepeats undergo different pathways to trigger cell apoptosis. J Mol Neurosci. 2011;43(3):225–34.

    Article  CAS  PubMed  Google Scholar 

  14. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21(24):4642–9.

    Article  PubMed  Google Scholar 

  15. Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood. 2005;106(4):1154–63.

    Article  CAS  PubMed  Google Scholar 

  16. Juliusson G, Antunovic P, Derolf A, Lehmann S, Mollgard L, Stockelberg D, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009;113(18):4179–87.

    Article  CAS  PubMed  Google Scholar 

  17. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453–74.

    Article  PubMed  Google Scholar 

  18. Campos-Mora M, Morales RA, Gajardo T, Catalan D, Pino-Lagos K. Neuropilin-1 in transplantation tolerance. Front Immunol. 2013;4(1):405.

    PubMed Central  PubMed  Google Scholar 

  19. Takagi S, Tsuji T, Amagai T, Takamatsu T, Fujisawa H. Specific cell surface labels in the visual centers of Xenopus laevis tadpole identified using monoclonal antibodies. Dev Biol. 1987;122(1):90–100.

    Article  CAS  PubMed  Google Scholar 

  20. Staton CA, Kumar I, Reed MW, Brown N. Neuropilins in physiological and pathological angiogenesis. J Pathol. 2007;212(3):237–48.

    Article  CAS  PubMed  Google Scholar 

  21. Matsushita A, Gotze T, Korc M. Hepatocyte growth factor-mediated cell invasion in pancreatic cancer cells is dependent on neuropilin-1. Cancer Res. 2007;67(21):10309–16.

    Article  CAS  PubMed  Google Scholar 

  22. Dabrowska M, Skoneczny M, Rode W. Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumor Biol. 2011;32(5):965–76.

    Article  CAS  Google Scholar 

  23. Pellet-Many C, Frankel P, Evans IM, Herzog B, Junemann-Ramirez M, Zachary IC. Neuropilin-1 mediates PDGF stimulation of vascular smooth muscle cell migration and signaling via p130Cas. Biochem J. 2011;435(3):609–18.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  24. Vilardi BM, Bravo-Calderon DM, Bemabe DG, Oliveira SH, Oliveira DT. VEGF-C expression in oral cancer by neurotransmitter-induced activation of beta-adrenergic receptors. Tumor Biol. 2013;34(1):139–43.

    Article  CAS  Google Scholar 

Download references

Conflicts of interest

We declare that we have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Hematology and Oncology, First Affiliated Hospital of the Xi’an Medical University, 48# Fenghao West Road, Xi’an, 710077, Shaanxi, China

    Jianqiang Zhao, Chengliang Li, Weiguo Ma & Zengfeng Ni

  2. Department of Hematology and Oncology, Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, 710004, China

    Liufang Gu

Authors
  1. Jianqiang Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Liufang Gu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chengliang Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Weiguo Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zengfeng Ni
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jianqiang Zhao.

Additional information

J. Zhao and L. Gu contributed equally to this study

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhao, J., Gu, L., Li, C. et al. Investigation of a novel biomarker, neuropilin-1, and its application for poor prognosis in acute myeloid leukemia patients. Tumor Biol. 35, 6919–6924 (2014). https://doi.org/10.1007/s13277-014-1942-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-014-1942-9

Keywords

Search

Navigation